53 related articles for article (PubMed ID: 17683572)
1. Systemic Metastasis of Pediatric Diffuse High-grade Astrocytoma: A Case Report.
Chiba K; Aihara Y; Oda Y; Masui K; Komori T; Yokoo H; Kawamata T
NMC Case Rep J; 2023; 10():265-271. PubMed ID: 37953909
[TBL] [Abstract][Full Text] [Related]
2. Integrative management of anaplastic astrocytoma through a combination of Ayurveda and conventional care: A case report.
Gautama PA; Subramanian N; Varma RG; Gangadharan GG
J Ayurveda Integr Med; 2023; 14(5):100748. PubMed ID: 37442646
[TBL] [Abstract][Full Text] [Related]
3. Current promising treatment strategy for glioblastoma multiform: A review.
Bahadur S; Sahu AK; Baghel P; Saha S
Oncol Rev; 2019 Jul; 13(2):417. PubMed ID: 31410248
[TBL] [Abstract][Full Text] [Related]
4. Systemic AAV9-IFNβ gene delivery treats highly invasive glioblastoma.
GuhaSarkar D; Su Q; Gao G; Sena-Esteves M
Neuro Oncol; 2016 Nov; 18(11):1508-1518. PubMed ID: 27194146
[TBL] [Abstract][Full Text] [Related]
5. Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide.
Matsuno A; Murakami M; Hoya K; Yamada SM; Miyamoto S; Yamada S; Son JH; Nishido H; Ide F; Nagashima H; Sugaya M; Hirohata T; Mizutani A; Okinaga H; Ishii Y; Tahara S; Teramoto A; Osamura RY
Med Mol Morphol; 2014 Mar; 47(1):1-7. PubMed ID: 23955641
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with rituximab and temozolomide for recurrent and refractory primary central nervous system lymphoma.
Murakami M; Fujimaki T; Asano S; Nakaguchi H; Yamada SM; Hoya K; Yamazaki K; Ishida Y; Matsuno A
Yonsei Med J; 2011 Nov; 52(6):1031-4. PubMed ID: 22028172
[TBL] [Abstract][Full Text] [Related]
7. MGMT immunoexpression in aggressive pituitary adenoma and carcinoma.
Lau Q; Scheithauer B; Kovacs K; Horvath E; Syro LV; Lloyd R
Pituitary; 2010 Dec; 13(4):367-79. PubMed ID: 20740317
[TBL] [Abstract][Full Text] [Related]
8. Treating malignant glioma in Chinese patients: update on temozolomide.
Chang L; Su J; Jia X; Ren H
Onco Targets Ther; 2014; 7():235-44. PubMed ID: 24600235
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of interferon-beta and temozolomide combination therapy against temozolomide-refractory recurrent anaplastic astrocytoma.
Fujimaki T; Ishii H; Matsuno A; Arai H; Nakagomi T
World J Surg Oncol; 2007 Aug; 5():89. PubMed ID: 17683572
[TBL] [Abstract][Full Text] [Related]
10. Interferon-β and temozolomide combination therapy for temozolomide monotherapy-refractory malignant gliomas.
Kawaji H; Tokuyama T; Yamasaki T; Amano S; Sakai N; Namba H
Mol Clin Oncol; 2015 Jul; 3(4):909-913. PubMed ID: 26171205
[TBL] [Abstract][Full Text] [Related]
11. Salvage therapy with temozolomide for recurrent or progressive high-grade gliomas refractory to ACNU [1-(4-amino-2-methyl-5-pyrimidynyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride].
Terasaki M; Tokutomi T; Shigemori M
Mol Med Rep; 2009; 2(3):417-21. PubMed ID: 21475844
[TBL] [Abstract][Full Text] [Related]
12. [Clinical trial updates for malignant brain tumors].
Wakabayashi T
Rinsho Shinkeigaku; 2011 Nov; 51(11):853-6. PubMed ID: 22277391
[TBL] [Abstract][Full Text] [Related]
13. Temozolomide Nonresponsiveness in Aggressive Prolactinomas and Carcinomas: Management and Outcomes.
Das L; Rai A; Salunke P; Ahuja CK; Sood A; Radotra BD; Sood R; Korbonits M; Dutta P
J Endocr Soc; 2022 Feb; 6(2):bvab190. PubMed ID: 35059545
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
